Aldeyra Therapeutics, Inc (ALDX) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) have earned a consensus rating of “Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $30.40.
A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $30.00 price target on shares of Aldeyra Therapeutics in a research report on Wednesday, November 14th. Janney Montgomery Scott upped their target price on Aldeyra Therapeutics to $28.00 and gave the company a “positive” rating in a research report on Thursday, September 27th. Canaccord Genuity reissued a “buy” rating and issued a $27.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, August 10th. ValuEngine raised Aldeyra Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. Finally, Zacks Investment Research downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 14th.
Hedge funds have recently added to or reduced their stakes in the business. Hillsdale Investment Management Inc. acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at approximately $131,000. National Asset Management Inc. acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at approximately $193,000. Rhumbline Advisers acquired a new stake in Aldeyra Therapeutics in the 2nd quarter valued at approximately $113,000. Athanor Capital LP acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at approximately $276,000. Finally, JBF Capital Inc. acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at approximately $276,000. Institutional investors own 69.10% of the company’s stock.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Wednesday, November 14th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). Equities research analysts expect that Aldeyra Therapeutics will post -1.83 EPS for the current fiscal year.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
See Also: What is a bull market?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.